Please assess the completion status of the following clinical trial:

Trial Title: A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria~1. Diagnosis of metastatic or advanced cancer that has failed standard effective therapy~2. Life expectancy of at least 12 weeks and adequate performance status~3. Adequate bone marrow, kidney and liver function~4. Willingness of male and female subjects who are not surgically sterile or post-menopausal to use adequate methods of birth control~Exclusion Criteria~1. Any anticancer chemotherapy, radiotherapy immunotherapy or investigational agents within 4 weeks of first dose of HKI-272~2. Inadequate cardiac function~3. Surgery within 2 weeks of first dose of HKI-272~4. Active central nervous system metastases (i.e., symptomatic, required use of corticosteroids and/or progressive growth)~5. Significant gastrointestinal disorder with diarrhea as a major symptom~6. Pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neratinib 80 mg (Type: EXPERIMENTAL): None
- Neratinib 160 mg (Type: EXPERIMENTAL): None
- Neratinib 240 mg (Type: EXPERIMENTAL): None
- Neratinib 320 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).